By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Castle Biosciences today announced it has licensed the BAP1 gene from Washington University in St. Louis for detecting metastasis in patients with melanoma.

The Friendswood, Texas-based firm has begun validation studies for use of the technology in both uveal melanoma, or ocular melanoma, and cutaneous melanoma and plans to incorporate the gene into its DecisionDx-UM assay. It also has an option for use of the gene for other cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.